You just read:

Tessa Therapeutics Announces Collaboration with Merck Investigating the Combination of KEYTRUDA® (pembrolizumab) and Virus-Specific T Cell Therapy Targeting Human Papillomavirus in Cervical Cancer

News provided by

Tessa Therapeutics

Apr 15, 2019, 19:15 ET